Biota Pharmaceuticals, Inc. to Present at the 8th Annual JMP Securities Healthcare Conference
ATLANTA, June 27, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 8th Annual JMP Securities Healthcare Conference at 2:30 p.m. EDT, July 10, 2013, at The St. Regis Hotel in New York City.
The presentation will be webcast live and may be accessed through the Investor Relations' Events and Presentations section on Biota's website at www.biotapharma.com . Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. An archived replay will also be available for 90 days following the live presentation.
Biota Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: Laninamivir octanoate, which the Company is developing for the treatment of influenza A and B infections in the U.S. through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad-spectrum capsid inhibitor of human rhinovirus. In addition to these clinical-stage programs, the Company has preclinical programs focused on developing treatments for respiratory syncytial virus and gram-negative, multi-drug resistant bacterial infections. For additional information about the Company, please visit www.biotapharma.com .
CONTACT: Russell H. Plumb Chief Executive Officer (678) 221-3351 email@example.com Hershel Berry Blueprint Life Science Group (415) 375-3340 firstname.lastname@example.org
Source: Biota Pharmaceuticals, Inc 2013 GlobeNewswire, Inc.